

H K E K C L K E K H K L K K K K K K



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(K % K % K K C %)

(Stock Code: 02196)

2013 THIRD QUARTERLY REPORT

本報告根據2013年9月13日（即2013年10月13日）生效的《香港聯合交易所有限公司證券上市規則》（“上市規則”）及《香港交易所證券上市規則》（“上市規則”）第571條（即《香港聯合交易所有限公司證券上市規則》）第13.09(2)條及第13.10B條的規定編製。

本報告所載資料乃根據本公司2013年9月30日（即2013年10月13日）的財務狀況編製。本公司（“Company”）及本集團（“Group”）均為在中華人民共和國（“PRC”）註冊的股份有限公司。本報告所載資料乃根據本集團在PRC境內註冊的子公司及分公司編製。

B O r r B r
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
C %

本報告所載資料乃根據本公司2013年9月30日（即2013年10月13日）的財務狀況編製。

A K G G K K K C F ; - K K G L ; C H % . H J , D . L - A D

* F K

Assets

Unit: RMB

Items	The Reporting Period (Jul - Sep)	From the beginning of the year to the end of the Reporting Period	Description
G	10,251,236.77	596,825,644.44	
G	2,878,850.90	13,168,079.40	
G			

§3 SIGNIFICANT EVENTS

3.1 Significant events that have a material effect on the financial position of the Group are as follows:

√ A N/A

Unit: million RMB

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Current assets	2,485,783,000.50	4,972,524,758.70	-50%	Majorly due to the decrease of cash and bank deposits in 2013
Trade receivables	1,316,781,579.78	907,307,576.06	45%	Majorly due to the increase of trade receivables in 2013
Inventory	7,615,057.77	17,674,707.55	-57%	Majorly due to the decrease of inventory in 2013
Intangible assets	2,368,367,750.12	1,752,799,860.87	35%	Majorly due to the increase of intangible assets in 2013
Development expenditure	42,946,124.18	29,475,413.33	46%	Majorly due to the increase of R&D expenditure in 2013
Goodwill	2,710,407,586.05	1,661,770,763.96	63%	Majorly due to the increase of goodwill in 2013
Other non-current assets	236,069,350.21	100,654,101.39	135%	Majorly due to the increase of other non-current assets in 2013
Deferred tax assets	72,033,067.63	31,482,514.80	129%	Majorly due to the increase of deferred tax assets in 2013
Prepaid expenses	1,199,559,074.08	519,422,250.00	131%	Majorly due to the increase of prepaid expenses in 2013
Deferred tax liabilities	12,240,519.57	4,725,748.28	159%	Majorly due to the increase of deferred tax liabilities in 2013
Other non-current liabilities	33,196,473.53	526,384,431.15	-94%	Majorly due to the decrease of other non-current liabilities in 2013

Income Statement				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Operating Profit	7,070,780,938.31	5,387,845,935.96	31%	Mainly due to the increase in the operating profit of the company in 2013.
Operating Loss	3,957,631,876.59	3,005,217,397.09	32%	Mainly due to the increase in the operating loss of the company in 2013.
Gain from disposal of assets (loss from disposal of assets)	39,511,717.28	-14,636,854.56	N/A	Mainly due to the gain from disposal of assets of the company in 2013.
Income tax expense	313,206,671.22	202,061,631.73	55%	Mainly due to the increase in the income tax expense of the company in 2013.
Net Profit	72,257,721.95	33,558,889.22	115%	Mainly due to the increase in the net profit of the company in 2013.
Other comprehensive income	285,252,496.15	-436,322,994.17	N/A	Mainly due to the increase in the other comprehensive income of the company in 2013.

Statement of Cash Flow				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Net Increase in Cash	-1,757,461,995.58	-368,977,652.38	376%	Mainly due to the increase in the net increase in cash of the company in 2013.

3.2 A. A N. B

O. 26 S. b. r 2013, (r. r. r) B. r 2013 3r (r. r. r) S. r. r. r C. R. r. r \$ r. I. S. r. r (r) \$ F. r. r. r (Gr. r) C., L. * O. 25 O. b. r 2013, CSRC “O. \$ F. r. r. r (Gr. r) C., L. R. r. r. A \$ r. I. S. r. r” (\$ \$ B. r H. [2013 N. 774). A. r. r. r CSRC, B. r R. r. r \$ r. I. S. r. r (r. r. r) \$ F. r. r. r (Gr. r) C., L. * b. r C. T. r. r. r (r. r. r. r) B. r 2013 (r. r. r. r)

3.2 对于任意给定的 $\epsilon > 0$, 存在 $\delta > 0$, 使得当 $|x - x_0| < \delta$ 时, 有 $|f(x) - f(x_0)| < \epsilon$.
 (即: 对于任意给定的 $\epsilon > 0$, 存在 $\delta > 0$, 使得当 $|x - x_0| < \delta$ 时, 有 $|f(x) - f(x_0)| < \epsilon$.
 对于任意给定的 $\epsilon > 0$, 存在 $\delta > 0$, 使得当 $|x - x_0| < \delta$ 时, 有 $|f(x) - f(x_0)| < \epsilon$.

3.3 对于任意给定的 $\epsilon > 0$, 存在 $\delta > 0$, 使得当 $|x - x_0| < \delta$ 时, 有 $|f(x) - f(x_0)| < \epsilon$.

$\square A \Rightarrow B \Leftrightarrow \sqrt{N} \cdot A \Rightarrow B$

3.4 对于任意给定的 $\epsilon > 0$, 存在 $\delta > 0$, 使得当 $|x - x_0| < \delta$ 时, 有 $|f(x) - f(x_0)| < \epsilon$.
 对于任意给定的 $\epsilon > 0$, 存在 $\delta > 0$, 使得当 $|x - x_0| < \delta$ 时, 有 $|f(x) - f(x_0)| < \epsilon$.
 对于任意给定的 $\epsilon > 0$, 存在 $\delta > 0$, 使得当 $|x - x_0| < \delta$ 时, 有 $|f(x) - f(x_0)| < \epsilon$.

$\square A \Rightarrow B \Leftrightarrow \sqrt{N} \cdot A \Rightarrow B$

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Li: **Chen Qiyu**

30 October 2013

Consolidated balance sheet (Continued)

30th 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
Paid-up capital (including share premium)	2,240,462,364.00	2,240,462,364.00
Reserves	4,396,998,107.25	4,287,287,930.01
Liabilities		
Short-term liabilities	1,338,476,598.49	1,338,476,598.49
Long-term liabilities		
Financial liabilities	6,621,610,997.36	5,703,028,462.15
Financial assets	-4,289,492.31	-10,462,767.38
Total assets less liabilities and provisions	14,593,258,574.79	13,558,792,587.27
Minority interests	1,889,445,595.04	1,745,855,848.86
Total	16,482,704,169.83	15,304,648,436.13
Total assets less liabilities and provisions	27,589,580,696.34	25,507,140,466.01

Liabilities
Current liabilities: Current liabilities

Financial liabilities
Financial liabilities: Financial liabilities

Financial assets
Financial assets: Financial assets

Balance sheet of the Parent Company

30th 2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and cash equivalents	967,810,425.06	2,804,108,583.37
Financial assets		
Receivables		
Prepaid expenses		
Inventory	112,185,785.22	98,972,778.68
Due from related parties	24,240,000.00	
Other receivables	1,207,151,982.57	941,562,545.17
Intangible assets	517,042.01	516,409.53
Non-current receivables		
Other non-current receivables	280,000,000.00	250,000,000.00
Total	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
Available-for-sale financial assets		
Holdings		
Long-term receivables		
Long-term investments	5,471,340,934.74	4,173,763,622.82
Intangible assets		
Fixed assets	20,153,012.47	20,815,349.96
Construction in progress		
Prepaid expenses		
Deferred tax assets		
Other non-current assets		
Intangible assets	3,215,662.67	3,496,198.41
Deferred tax assets		
Goodwill		
Long-term investments		
Deferred tax assets		
Other non-current assets	4,470,831,299.40	4,035,133,683.09
Total	9,965,540,909.28	8,233,208,854.28
Total	12,557,446,144.14	12,328,369,171.03

Consolidated Income Statement

July – September 2013

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB Tenthousand Yuan

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Total	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income: Operating	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income				
Expenses				
Financial				
II. Total	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
Income: Operating	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
Income				
Expenses				
Provision				
Cost				
Non-operating				
Profit				
Assets				
Beginning	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
Share	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
Assets	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
Expenses	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
Assets	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Profit: Government	-548,949.75	-4,627,534.57	39,511,717.28	-14,636,854.56
Income: Government	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
Income: Government	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
Expenses: Government				
III. Operating	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Profit: Non-operating	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
Loss: Non-operating	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
Income: Loss	260,198.27	-243,201.72	979,886.77	946,040.98

Income Statement of the Parent Company

July – September 2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB Tenthousand Yuan

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Operating Income				
: Operating Income				
: Other Income				
: Selling Expenses				
: Administrative Expenses	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
: Financial Expenses	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
: Assets Impairment Losses				
: Government Subsidies				
: Income Tax Expenses	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
: Income Tax Expenses	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Operating Loss ("–")	-34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
: Non-current Assets Impairment Losses	76,900.00	234,093.38	236,049.11	734,093.38
: Non-current Assets Impairment Losses		-570,000.00	2,514,544.42	860,000.00
: Losses on Disposal of Long-term Assets			5,725.77	
III. Total ("–")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
: Income Tax Expenses				
IV. Net Loss ("–")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
: Earnings				
(1) basic earnings				
(2) diluted earnings				
: Other Comprehensive Income			51,779.40	27,699,470.25
II. Total	-34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

Li Rongfeng
Chairman

Guo Fei
President

Duan Rongfeng
Director

Statement of Cash Flow of the Parent Company (Continued)

J - 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
III. Cash flow generated from financing activities:		
Cash received from the sale of equity		
Cash received from the sale of debt	255,115,078.77	
Cash received from the sale of assets		1,486,950,000.00
Operating activities	1,904,031,173.98	4,295,169,165.49
Subsidiary activities	2,159,146,252.75	5,782,119,165.49
Cash received from the sale of investments	790,115,078.77	454,000,000.00
Cash received from the sale of property, plant and equipment	674,744,025.09	302,177,196.32
Operating activities	2,109,471,293.35	5,478,222,986.00
Subsidiary activities	3,574,330,397.21	6,234,400,182.32
Net change in cash and cash equivalents	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
Period beginning balance	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

L. R. : C. Q.

G. F. : H. J.

D. r. : D. J.